Incidence of intravenous colistin nephrotoxicity in hospitalized patients

被引:2
作者
Espinoza, Cristian Rosas [1 ]
Caro Teller, Jose Manuel [1 ]
de la Calle, Guillermo Maestro [2 ]
Loitegui, Maria Arrieta [1 ]
Ferrari Piquero, Jose Miguel [1 ]
机构
[1] Hosp Univ 12 Octubre, Serv Farm Hosp, Madrid, Spain
[2] Hosp Univ 12 Octubre, Serv Med Interna, Madrid, Spain
关键词
colistin; drug toxicity; risk factors;
D O I
10.37201/req/082.2020
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Objectives. The increase in infections with multidrug resistant bacteria has forced to return to the use of colistin, antibiotic with known nephrotoxicity. The aim of the study is to determine the incidence of colistin nephrotoxicity nowadays. Material and methods. Retrospective-observational-unicentric study was collected hospitalized patients in intravenous colistin treatment during the years 2018-2019. Nephrotoxicity was defined according to the RIFLE scale. The variables to determine it were serum creatinine (sCr) and glomerular filtration (GF). The variables analyzed were age, sex, treatment duration, loading and cumulative dose, empirical/targeted treatment, chronic kidney disease, concomitant use of intravenous contrast and nephrotoxic drugs. Results. A total of 90 patients (60% men) were included, with an average age of 58.2 +/- 18.1 years. The mean duration of treatment was 9 +/- 8.3 days, with an average cumulative dose of 69.8 +/- 71MU. There were no differences between sCr and GF at the beginning and end of treatment. The incidence of nephrotoxicity was 1.73 cases/100 days of treatment (prevalence of 15.56%). Conclusions. Colistin nephrotoxicity has an important incidence, without developing severe illness.
引用
收藏
页码:12 / 17
页数:6
相关论文
共 14 条
[1]  
Agencia Espanola de Medicamentos y Productos Sanitarios, FICH TECN COL INTR
[2]  
[Anonymous], 2019, PLAN NACL RESISTENCI
[3]   Treatment of Infections Due to MDR Gram-Negative Bacteria [J].
Bassetti, Matteo ;
Peghin, Maddalena ;
Vena, Antonio ;
Giacobbe, Daniele Roberto .
FRONTIERS IN MEDICINE, 2019, 6
[4]   Molecular Mechanisms of Colistin-Induced Nephrotoxicity [J].
Gai, Zhibo ;
Samodelov, Sophia L. ;
Kullak-Ublick, Gerd A. ;
Visentin, Michele .
MOLECULES, 2019, 24 (03)
[5]   A review on colistin nephrotoxicity [J].
Javan, Atefeh Ordooei ;
Shokouhi, Shervin ;
Sahraei, Zahra .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (07) :801-810
[6]  
Jorge Morales B., 2010, REV MED CLIN CONDES, V21, P623, DOI 10.1016/S0716-8640(10)70578-2
[7]   Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections [J].
Li, Jian ;
Nation, Roger L. ;
Turnidge, John D. ;
Milne, Robert W. ;
Coulthard, Kingsley ;
Rayner, Craig R. ;
Paterson, David L. .
LANCET INFECTIOUS DISEASES, 2006, 6 (09) :589-601
[8]   Shedding light on the use of colistin: still gaps to be filled [J].
Luque, Sonia ;
Grau, Santiago ;
Berenguer, Nuria ;
Pablo Horcajada, Juan ;
Sorli, Luisa ;
Milagro Montero, Maria ;
Salas, Esther .
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2011, 29 (04) :287-296
[9]   Management of Infection and Febrile Neutropenia in Patients with Solid Cancer [J].
Maria Aguado, Jose ;
Jesus Cruz, Juan ;
Antonio Virizuela, Juan ;
Aguilar, Manuela ;
Carmona, Alberto ;
Cassinello, Javier ;
Gudiol, Carlota ;
Jimenez Fonseca, Paula ;
Lizasoain, Manuel ;
Marco, Francesc ;
Ruiz, Isabel ;
Ruiz, Maribel ;
Salavert, Miguel ;
Vicente, David ;
Carratala, Jordi .
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2017, 35 (07) :451-460
[10]  
Martínez J, 2014, REV NEFROL DIAL TRAS, V34, P108